Reduction of HLA class I expression by ribonucleic acid interference mitigates allogenicity of human primary and Immortalized cells.

Nathan A. Lemp, Kazunori Haga, Katrin Hacke, Janet A. Treger, Brooke T. Bogan, Emmanuelle Faure-Kumar, Christopher R. Logg, Carol A. Kruse, James C. Cicciarelli, Noriyuki Kasahara

Research output: Contribution to journalArticle

Abstract

Unmatched human leukocyte antigens (HLA) expressed by allogeneic donor cells are the major target for immunological rejection. In order to reduce the immunogenicity of allograft cells, we have developed lentiviral vectors for delivery of short hairpin ribonucleic acid (shRNA) against Class I HLA. This approach was evaluated in both an established human embryonic kidney cell line and primary human CD34+ hematopoietic stem/progenitor cells. Target cells transduced with lentiviral vectors expressing either HLA-A*0201 allele-specific or HLA-A, -B, -C consensus sequence-specific shRNA showed effective knockdown of cell surface HLA expression. Mixed lymphocyte-target cell reactions showed significantly reduced interferon-gamma production from alloreactive cytotoxic T lymphocytes and significantly reduced levels of target cell apoptosis after shRNA-mediated knockdown of HLA expression and target cell survival correlated with vector transduction efficiency. Furthermore, increasing resistance to complement-dependent cytotoxicity mediated by anti-HLA antibodies was observed to correlate with increasing levels of shRNA vector transduction in primary human CD34+ cells. Notably, non-HLA restricted killing by lymphokine-activated killer cells was not incurred after HLA knockdown. These data demonstrate the potential for genetic engineering strategies targeting incompatible HLA alleles to reduce both cellular and humoral responses and enable graft survival after transplantation of allogeneic cells and tissues.

Original languageEnglish (US)
Pages (from-to)93-101
Number of pages9
JournalClinical transplants
StatePublished - 2013
Externally publishedYes

Fingerprint

HLA Antigens
RNA
Hematopoietic Stem Cells
Alleles
Lymphokine-Activated Killer Cells
Tissue Transplantation
Genetic Engineering
Cell Transplantation
Homologous Transplantation
Consensus Sequence
Cytotoxic T-Lymphocytes
Graft Survival
Interferon-gamma
Allografts
Cell Survival
Lymphocytes
Apoptosis
Kidney
Cell Line
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reduction of HLA class I expression by ribonucleic acid interference mitigates allogenicity of human primary and Immortalized cells. / Lemp, Nathan A.; Haga, Kazunori; Hacke, Katrin; Treger, Janet A.; Bogan, Brooke T.; Faure-Kumar, Emmanuelle; Logg, Christopher R.; Kruse, Carol A.; Cicciarelli, James C.; Kasahara, Noriyuki.

In: Clinical transplants, 2013, p. 93-101.

Research output: Contribution to journalArticle

Lemp, NA, Haga, K, Hacke, K, Treger, JA, Bogan, BT, Faure-Kumar, E, Logg, CR, Kruse, CA, Cicciarelli, JC & Kasahara, N 2013, 'Reduction of HLA class I expression by ribonucleic acid interference mitigates allogenicity of human primary and Immortalized cells.', Clinical transplants, pp. 93-101.
Lemp, Nathan A. ; Haga, Kazunori ; Hacke, Katrin ; Treger, Janet A. ; Bogan, Brooke T. ; Faure-Kumar, Emmanuelle ; Logg, Christopher R. ; Kruse, Carol A. ; Cicciarelli, James C. ; Kasahara, Noriyuki. / Reduction of HLA class I expression by ribonucleic acid interference mitigates allogenicity of human primary and Immortalized cells. In: Clinical transplants. 2013 ; pp. 93-101.
@article{34495af9bb444c63a15bf6f68fab8933,
title = "Reduction of HLA class I expression by ribonucleic acid interference mitigates allogenicity of human primary and Immortalized cells.",
abstract = "Unmatched human leukocyte antigens (HLA) expressed by allogeneic donor cells are the major target for immunological rejection. In order to reduce the immunogenicity of allograft cells, we have developed lentiviral vectors for delivery of short hairpin ribonucleic acid (shRNA) against Class I HLA. This approach was evaluated in both an established human embryonic kidney cell line and primary human CD34+ hematopoietic stem/progenitor cells. Target cells transduced with lentiviral vectors expressing either HLA-A*0201 allele-specific or HLA-A, -B, -C consensus sequence-specific shRNA showed effective knockdown of cell surface HLA expression. Mixed lymphocyte-target cell reactions showed significantly reduced interferon-gamma production from alloreactive cytotoxic T lymphocytes and significantly reduced levels of target cell apoptosis after shRNA-mediated knockdown of HLA expression and target cell survival correlated with vector transduction efficiency. Furthermore, increasing resistance to complement-dependent cytotoxicity mediated by anti-HLA antibodies was observed to correlate with increasing levels of shRNA vector transduction in primary human CD34+ cells. Notably, non-HLA restricted killing by lymphokine-activated killer cells was not incurred after HLA knockdown. These data demonstrate the potential for genetic engineering strategies targeting incompatible HLA alleles to reduce both cellular and humoral responses and enable graft survival after transplantation of allogeneic cells and tissues.",
author = "Lemp, {Nathan A.} and Kazunori Haga and Katrin Hacke and Treger, {Janet A.} and Bogan, {Brooke T.} and Emmanuelle Faure-Kumar and Logg, {Christopher R.} and Kruse, {Carol A.} and Cicciarelli, {James C.} and Noriyuki Kasahara",
year = "2013",
language = "English (US)",
pages = "93--101",
journal = "Clinical transplants",
issn = "0890-9016",
publisher = "UCLA Immunogenetics Center",

}

TY - JOUR

T1 - Reduction of HLA class I expression by ribonucleic acid interference mitigates allogenicity of human primary and Immortalized cells.

AU - Lemp, Nathan A.

AU - Haga, Kazunori

AU - Hacke, Katrin

AU - Treger, Janet A.

AU - Bogan, Brooke T.

AU - Faure-Kumar, Emmanuelle

AU - Logg, Christopher R.

AU - Kruse, Carol A.

AU - Cicciarelli, James C.

AU - Kasahara, Noriyuki

PY - 2013

Y1 - 2013

N2 - Unmatched human leukocyte antigens (HLA) expressed by allogeneic donor cells are the major target for immunological rejection. In order to reduce the immunogenicity of allograft cells, we have developed lentiviral vectors for delivery of short hairpin ribonucleic acid (shRNA) against Class I HLA. This approach was evaluated in both an established human embryonic kidney cell line and primary human CD34+ hematopoietic stem/progenitor cells. Target cells transduced with lentiviral vectors expressing either HLA-A*0201 allele-specific or HLA-A, -B, -C consensus sequence-specific shRNA showed effective knockdown of cell surface HLA expression. Mixed lymphocyte-target cell reactions showed significantly reduced interferon-gamma production from alloreactive cytotoxic T lymphocytes and significantly reduced levels of target cell apoptosis after shRNA-mediated knockdown of HLA expression and target cell survival correlated with vector transduction efficiency. Furthermore, increasing resistance to complement-dependent cytotoxicity mediated by anti-HLA antibodies was observed to correlate with increasing levels of shRNA vector transduction in primary human CD34+ cells. Notably, non-HLA restricted killing by lymphokine-activated killer cells was not incurred after HLA knockdown. These data demonstrate the potential for genetic engineering strategies targeting incompatible HLA alleles to reduce both cellular and humoral responses and enable graft survival after transplantation of allogeneic cells and tissues.

AB - Unmatched human leukocyte antigens (HLA) expressed by allogeneic donor cells are the major target for immunological rejection. In order to reduce the immunogenicity of allograft cells, we have developed lentiviral vectors for delivery of short hairpin ribonucleic acid (shRNA) against Class I HLA. This approach was evaluated in both an established human embryonic kidney cell line and primary human CD34+ hematopoietic stem/progenitor cells. Target cells transduced with lentiviral vectors expressing either HLA-A*0201 allele-specific or HLA-A, -B, -C consensus sequence-specific shRNA showed effective knockdown of cell surface HLA expression. Mixed lymphocyte-target cell reactions showed significantly reduced interferon-gamma production from alloreactive cytotoxic T lymphocytes and significantly reduced levels of target cell apoptosis after shRNA-mediated knockdown of HLA expression and target cell survival correlated with vector transduction efficiency. Furthermore, increasing resistance to complement-dependent cytotoxicity mediated by anti-HLA antibodies was observed to correlate with increasing levels of shRNA vector transduction in primary human CD34+ cells. Notably, non-HLA restricted killing by lymphokine-activated killer cells was not incurred after HLA knockdown. These data demonstrate the potential for genetic engineering strategies targeting incompatible HLA alleles to reduce both cellular and humoral responses and enable graft survival after transplantation of allogeneic cells and tissues.

UR - http://www.scopus.com/inward/record.url?scp=84906953173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906953173&partnerID=8YFLogxK

M3 - Article

C2 - 25095496

AN - SCOPUS:84906953173

SP - 93

EP - 101

JO - Clinical transplants

JF - Clinical transplants

SN - 0890-9016

ER -